RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
9 Meters Biopharma Stock

9 Meters Biopharma Stocks 2024

9 Meters Biopharma Stocks

12.96 M

Ticker

NMTR

ISIN

US6544051096

WKN

A2P362

In 2024, 9 Meters Biopharma had 12.96 M outstanding stocks, a 0% change from the 12.96 M stocks in the previous year.

The 9 Meters Biopharma Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2028e12.96
2027e12.96
2026e12.96
2025e12.96
2024e12.96
2023e12.96
202212.96
202112.16
2020105.64
20191.67
20181.24
20170.05
20160.55
20150.81
20140.81
20130.81

9 Meters Biopharma shares outstanding

The number of shares was 9 Meters Biopharma in 2023 — This indicates how many shares 12.956 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue 9 Meters Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates 9 Meters Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of 9 Meters Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating 9 Meters Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

9 Meters Biopharma Aktienanalyse

What does 9 Meters Biopharma do?

9 Meters Biopharma Inc is a company that specializes in researching, developing, and marketing innovative therapeutic treatment options for various chronic diseases. Founded in 2010, the company has since become a major player in the biopharmaceutical drug development industry. The main goal of 9 Meters Biopharma is to provide new and effective treatment options to patients suffering from chronic diseases. The company focuses on the areas of gastroenterology, oncology, autoimmune diseases, and rare diseases. Its business model is based on identifying promising drug candidates and conducting clinical trials to prove the effectiveness and safety of the drugs. Once a drug is successfully developed, the company focuses on marketing and distributing the medication. One of the company's key products is the drug NMIL1701, which is developed for the treatment of patients with celiac disease. The medication targets the breakdown of gluten, which is present in many foods and can cause an inappropriate immune response and chronic inflammation in the intestines of people with celiac disease. Additionally, the company is currently developing medications for the treatment of ulcerative colitis, Crohn's disease, and pancreatitis. It is also researching the development of drugs for the treatment of various cancers and autoimmune diseases, including multiple sclerosis, lupus, and rheumatoid arthritis. Another important aspect of 9 Meters Biopharma's activities is collaborating with other companies and organizations to accelerate and improve drug development. The company works with various academic institutions and research organizations to jointly work on the development of new therapies. Overall, 9 Meters Biopharma Inc has established itself as a dynamic and innovative company in the biopharmaceutical landscape. With its strong focus on the development of novel therapies and collaboration with other organizations, the company is likely to continue playing a major role in improving healthcare and treating chronic diseases. 9 Meters Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating 9 Meters Biopharma's Shares Outstanding

9 Meters Biopharma's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in 9 Meters Biopharma’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding 9 Meters Biopharma’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in 9 Meters Biopharma’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about 9 Meters Biopharma stock

How many stocks are there of 9 Meters Biopharma?

The current number of stocks of 9 Meters Biopharma is 12.96 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of 9 Meters Biopharma are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of 9 Meters Biopharma evolved in recent years?

The number of shares of 9 Meters Biopharma has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. 9 Meters Biopharma as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of 9 Meters Biopharma?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does 9 Meters Biopharma pay?

Over the past 12 months, 9 Meters Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, 9 Meters Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of 9 Meters Biopharma?

The current dividend yield of 9 Meters Biopharma is .

When does 9 Meters Biopharma pay dividends?

9 Meters Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of 9 Meters Biopharma?

9 Meters Biopharma paid dividends every year for the past 0 years.

What is the dividend of 9 Meters Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is 9 Meters Biopharma located?

9 Meters Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von 9 Meters Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of 9 Meters Biopharma from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did 9 Meters Biopharma pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of 9 Meters Biopharma in the year 2023?

In the year 2023, 9 Meters Biopharma distributed 0 USD as dividends.

In which currency does 9 Meters Biopharma pay out the dividend?

The dividends of 9 Meters Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von 9 Meters Biopharma

Our stock analysis for 9 Meters Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 9 Meters Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.